Definitive Healthcare (NASDAQ:DH) Releases Q2 Earnings Guidance

Definitive Healthcare (NASDAQ:DH) updated its second quarter earnings guidance on Tuesday. The company provided earnings per share guidance of $0.08-$0.09 for the period, compared to the consensus earnings per share estimate of $0.09. The company issued revenue guidance of $62.0-$63.5 million, compared to the consensus revenue estimate of $65.19 million. Definitive Healthcare also updated its FY24 guidance to $0.36-$0.38 EPS.

Definitive Healthcare Price Performance

NASDAQ:DH traded down $1.90 during trading hours on Wednesday, hitting $5.35. The stock had a trading volume of 5,266,918 shares, compared to its average volume of 613,781. The firm has a market capitalization of $630.18 million, a price-to-earnings ratio of -3.01, a P/E/G ratio of 6.12 and a beta of 1.41. Definitive Healthcare has a one year low of $4.38 and a one year high of $12.45. The company has a 50 day simple moving average of $7.70 and a two-hundred day simple moving average of $8.29. The company has a debt-to-equity ratio of 0.20, a current ratio of 2.31 and a quick ratio of 2.31.

Definitive Healthcare (NASDAQ:DH) last issued its quarterly earnings data on Wednesday, February 28th. The company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.02). The business had revenue of $65.93 million for the quarter, compared to analysts’ expectations of $66.01 million. Definitive Healthcare had a positive return on equity of 0.43% and a negative net margin of 80.40%. Research analysts forecast that Definitive Healthcare will post 0.11 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on DH. Morgan Stanley downgraded shares of Definitive Healthcare from an overweight rating to an equal weight rating and lowered their price target for the stock from $11.50 to $9.00 in a research note on Wednesday. Canaccord Genuity Group cut their target price on shares of Definitive Healthcare from $10.00 to $8.00 and set a hold rating on the stock in a research note on Wednesday. Needham & Company LLC reissued a hold rating on shares of Definitive Healthcare in a research note on Wednesday. Barclays lifted their price objective on Definitive Healthcare from $10.00 to $11.00 and gave the company an equal weight rating in a research report on Friday, March 1st. Finally, Stifel Nicolaus decreased their target price on Definitive Healthcare from $11.00 to $9.50 and set a buy rating for the company in a research report on Wednesday. Eight equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of Hold and a consensus price target of $10.81.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.